Multifunctional Nanoassemblies for Ligand-directed Imaging and Therapy of Endocri
用于内分泌配体定向成像和治疗的多功能纳米组件
基本信息
- 批准号:8735865
- 负责人:
- 金额:$ 33.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-01 至 2016-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdenocarcinomaAdhesionsArchivesAreaBacteriophagesBlood VesselsCancer BiologyCancer CenterCollaborationsComputer SimulationDetectionDevelopmentDiseaseDrug CarriersEarly DiagnosisEndocrineEngineeringGenerationsGoldHeatingHomingHumanImageImmunohistochemistryInfrared RaysIslet Cell TumorLigandsLiposomesMalignant NeoplasmsMalignant neoplasm of ovaryMethodsModalityMolecularNanotechnologyOutputOvarianPancreasPeptide LibraryPhage DisplayPharmacologic SubstancePositron-Emission TomographyPropertyRaman Spectrum AnalysisRelative (related person)SamplingScienceServicesShapesSignal TransductionSiliconSpecificityStreptozocinSurfaceSurface PropertiesSystemTexasTherapeuticTherapeutic AgentsTherapeutic EffectThermal Ablation TherapyTissuesTracerTransgenic MiceTranslatingVascular EndotheliumX-Ray Computed Tomographyangiogenesisbasebiomathematicschemical propertychemotherapyclinical applicationcombinatorialdensitydesignhuman diseaseimaging probein vivomathematical modelmolecular imagingmouse modelnanonanoassemblynanoengineeringnanomedicinenanoparticlenoveloncologyovarian neoplasmpancreatic neoplasmparticlephysical propertyreceptorreceptor expressionresponsescaffoldscreeningselective expressionsimulationtargeted deliverytooltool developmenttumorvascular bed
项目摘要
PROJECT TITLE: Multifunctional Nanoassemblies for Ligand-Directed Imaging and Therapy of Endocrine Pancreatic Tumors
PROJECT SUMMARY: The development of tools for the targeted delivery of Imaging-probes and therapeufic agents has become the focus of intense efforts in the context of many human diseases. The in vivo screening method in which phage can be selected from engineered combinatorial peptide libraries for their ability to target specific vascular beds has uncovered a vascular address system that allows specific angiogenesis-related targeting to blood vessels in cancer. This phage display-based targeting Is expanded by the direct-assembly of gold and nanoporous silicon nanoparticles onto phage for nanomedical applications. Through exploiting the nanodimensions of the phage particle as a molecular network we generated biologically active nanoassemblies (NAs) with concomitant unique and tunable chemical and physical properties. These properties include near-infrared (NIR) radiation conversion to heat, enhancement of fluorescent signals, NIR surface enhanced Raman scattering (SERS) and the ability to conjugate and incorporate therapies or imaging-tracers. This tuning capability combined with the programmable tissue targefing affords the Integrafion of multiple funcfionalities into a single NA and serves as a complementary and non-mutually exclusive tool among different applicafions, including chemotherapy targeting and molecular imaging. Project 4 aims to develop the ligand-directed Si particles- phage- Au particles NAs as novel systems for targeted imaging and therapy in endocrine pancreatic tumors. These efforts will be translated into wide-ranging clinical applications.
项目标题:用于胰腺内分泌肿瘤的配体导向成像和治疗的多功能纳米组件
项目概述:在许多人类疾病的背景下,开发定向递送成像探头和治疗剂的工具已成为紧张努力的重点。体内筛选方法可以从工程组合肽库中选择噬菌体,因为它们具有靶向特定血管床的能力,该方法揭示了一种血管地址系统,该系统允许在癌症中针对血管生成相关的特定靶向。这种基于噬菌体展示的靶向是通过将金和纳米多孔硅纳米颗粒直接组装到噬菌体上用于纳米医学应用而扩展的。通过利用噬菌体颗粒的纳米尺寸作为分子网络,我们产生了具有生物活性的纳米组件(NAS),具有伴随的独特的和可调节的化学和物理性质。这些特性包括近红外(NIR)辐射到热的转换、荧光信号的增强、近红外表面增强拉曼散射(SERS)以及结合和整合疗法或成像示踪剂的能力。这种调谐能力与可编程的组织靶标相结合,将多种功能集成到单个NA中,并在不同的应用之间充当互补和非互斥的工具,包括化疗靶向和分子成像。项目4旨在开发配体导向的硅颗粒-噬菌体-金颗粒Nas作为胰腺内分泌肿瘤靶向成像和治疗的新系统。这些努力将转化为广泛的临床应用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN K. LIBUTTI其他文献
STEVEN K. LIBUTTI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN K. LIBUTTI', 18)}}的其他基金
Rutgers Optimizes Innovation (ROI) Program
罗格斯大学优化创新 (ROI) 计划
- 批准号:
10316635 - 财政年份:2020
- 资助金额:
$ 33.02万 - 项目类别:
Rutgers Optimizes Innovation (ROI) Program
罗格斯大学优化创新 (ROI) 计划
- 批准号:
10475236 - 财政年份:2019
- 资助金额:
$ 33.02万 - 项目类别:
Rutgers Optimizes Innovation (ROI) Program
罗格斯大学优化创新 (ROI) 计划
- 批准号:
10022340 - 财政年份:2019
- 资助金额:
$ 33.02万 - 项目类别:
Rutgers Optimizes Innovation (ROI) Program
罗格斯大学优化创新 (ROI) 计划
- 批准号:
10240645 - 财政年份:2019
- 资助金额:
$ 33.02万 - 项目类别:
Training of Surgeons for Studies of the Tumor Microenvironment
外科医生肿瘤微环境研究培训
- 批准号:
8999649 - 财政年份:2015
- 资助金额:
$ 33.02万 - 项目类别:
Development of Standardized Electronic Treatment Plan Builds for NCI-Supported Clinical Trials Applicable Across Clinical Research Sites; In conjunction with the Big Ten EHR Consortium
为 NCI 支持的临床试验开发标准化电子治疗计划,适用于各个临床研究中心;
- 批准号:
10225772 - 财政年份:1997
- 资助金额:
$ 33.02万 - 项目类别:
T-Cell Receptor Discovery for Engineered T-cell Therapy for Human Cancers
用于人类癌症工程 T 细胞疗法的 T 细胞受体发现
- 批准号:
10317346 - 财政年份:1997
- 资助金额:
$ 33.02万 - 项目类别:
Development of Standardized Electronic Treatment Plan Builds for NCI-Supported Clinical Trials Applicable Across Clinical Research Sites; In conjunction with the Big Ten EHR Consortium-Year 2
为 NCI 支持的临床试验开发标准化电子治疗计划,适用于各个临床研究中心;
- 批准号:
10442814 - 财政年份:1997
- 资助金额:
$ 33.02万 - 项目类别:
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 33.02万 - 项目类别: